Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Latar Belakang: Karsinoma payudara invasif adalah keganasan payudara yang berasal dari proliferasi epitel duktus/asinus payudara. Seiring berjalannya waktu terjadi perubahan molekular menjadi karakteristik yang lebih agresif dan menyebabkan kurang respons terhadap terapi. Kemoterapi berbasis anthracycline dan taxane umum digunakan pada tatalaksana karsinoma payudara invasif. Kemoterapi tersebut pada umumnya berfokus dalam menekan proliferasi. Kemampuan anti-apoptosis sel tumor membuat sel tumor sulit dieliminasi. NF-kB/p65 merupakan faktor transkripsi yang berperan dalam regulasi anti-apoptosis. Tujuan: Penelitian ini bertujuan untuk mengetahui hubungan ekspresi NF-kB/p65 dengan respons terapi serta perbandingan ekspresi NF-kB/p65 sebelum dan sesudah kemoterapi neoadjuvan pada kasus karsinoma payudara invasif. Metode: Penelitian analitik observasional dengan desain cross sectional pada kasus karsinoma payudara invasif yang mendapatkan kemoterapi berbasis anthracycline serta kombinasi anthracycline dan taxane dengan siklus kemoterapi lengkap di RSCM periode Januari 2015 sampai Desember 2021. Pengambilan sampel penelitian dilakukan secara consecutive sampling pada blok parafin sediaan biopsi (sebelum kemoterapi neoadjuvan) yang berpasangan dengan sediaan operasi (sesudah kemoterapi neoadjuvan), kemudian dilakukan pemeriksaan imunohistokimia NF-kB/p65 dan dianalisis dengan uji Fisher’s exact. Hasil: Dari 21 kasus, 4 kasus (19%) tidak respons terapi dan 17 kasus (81%) respons terapi. Pada 2 kasus respons komplet, 1 kasus NF-kB/p65 terekspresi dan 1 kasus lainnya NF-kB/p65 tidak terekspresi pada sediaan biopsi (sebelum kemoterapi neoadjuvant). Kedua kasus tersebut tidak mengekspresikan NF-kB/p65 pada sediaan operasi (sesudah kemoterapi neoadjuvan). NF-kB/p65 yang terekspresi menunjukkan pasien yang tidak respons terapi dan respons parsial, namun tidak bermakna secara statistik (p>0,05). Hasil analisis ekspresi NFkB p65 sebelum dan sesudah kemoterapi tidak bermakna (p=0,095). Kesimpulan: Terekspresinya NF-kB/p65 ditemukan pada respons terapi patologik yang tidak respons dan respons parsial. Ekspresi NF-kB/p65 sebelum dan sesudah kemoterapi menunjukkan ekspresi yang sama. ......Background: Invasive breast carcinoma is a breast malignancy originating from proliferation of the ductal/acini epithelium of breast. Overtime, there are molecular changes that become more aggressive characteristics and cause less response to therapy. Anthracycline-based and taxane-based chemotherapy are commonly used in the treatment of breast carcinoma. Chemotherapy generally focuses on suppressing proliferation. The anti-apoptotic ability of tumour cells make it difficult to eliminate tumour cells. NF-kB/p65 is a transcription factor that plays a role in anti-apoptotic regulation. Objectives: This study aims to determine the relationship between NF-kB/p65 expression and therapy response before and after neoadjuvant chemotherapy in invasive breast carcinoma cases. Methods: An observational analytic study with a cross sectional design in invasive breast carcinoma’s specimens treated with anthracycline-based and combination with taxane chemotherapy at RSUPN Dr. dr. Cipto Mangunkusumo from January 2015 until December 2021. The study sample was taken by consecutive sampling from block paraffin biopsy preparation (before neoadjuvant chemotherapy) paired with surgical preparation (after neoadjuvant chemotherapy), then NF-kB/p65 immunohistochemistry examination was performed and analyzed by Fisher’s exact test. Results: Of the 21 cases, 4 cases (19%) did not respond to therapy and 17 cases (81%) respond. In two cases of complete response, one case expressed NF-kB/p65 and other case was not expressed in biopsy specimen. Both cases did not expressed NF-kB/p65 in operation specimen. NF-kB/p65 expressed show in patients who did not respond to therapy and partial response, but not statistically significant (p>0.05). The result of analysis NF-kB/p65 expression before and after chemotherapy were not significant (p=0.095). Conclusion: Expression of NF-kB/p65 was found in partial response and no response to chemotherapy neoadjuvant. Expression of NF-kB/p65 before and after chemotherapy neoadjuvant showed same expression.

Abstrak :
Latar Belakang: Karsinoma narofaring (KNF) termasuk kanker dengan prevalensi yang cukup tinggi di Indonesia dengan prognosis yang cukup. Dalam menentukan progresifitas suatu kanker, didapatkan peranan penting dari penurunan tumor supresor gen dan peningkatan proliferasi. Hal tersebut ditandai oleh marker p53 sebagai gen supresor yang menginduksi apoptosis dan Ki67 sebagai marker proliferasi sel. Hingga saat ini belum terdapat penelitian mengenai hubungan overekspresi p53 dan Ki67 terhadap respon kemoradiasi dan analisis kesintasan selama 3 tahun pada KNF stadium lokal lanjut. Tujuan: Mencari hubungan antara overekspresi p53 dan Ki67 terhadap respon kemoradiasi dan kesintasan 3 tahun pasien KNF stadium lokal lanjut. Metode: Penelitian ini merupakan penelitian analitik observasional dengan desain analisis kesintasan. Penelitian ini menggunakan desain penelitian kohort retrospektif, dengan pengambilan data dari rekam medis kemudian ditelusuri riwayat perjalanan penyakitnya. Sample penelitian berupa jaringan pada blok parafin pasien KNF stadium lokal lanjut yang diambil secara consecutive sampling dari populasi penelitian dari periode 2015–2017 di RSUPN Dr. Cipto Mangunkusumo sejumlah 82 orang. Hasil: Dari total 82 pasien KNF stadium local lanjut, terdapat 65 pasien kelamin laki – laki (79,3%) dan 17 pasien perempuan (20,7%), dengan usia paling banyak pada kelompok 41 – 50 tahun sebanyak 31,8%. Overekspresi p53 ditemukan pada 36 pasien (43,9%), sementara overekspresi Ki67 ditemukan pada 35 pasien (42,7%). Dari respon kemoradiasi, pasien dengan overekspresi p53 dan Ki67 berpeluang memberikan respon negatif yang lebih tinggi dibandingkan dengan low ekspresi (RR = 3,052 dengan IK95%: 1,777 – 5,242, p = 0,009; RR = 2,573 dengan IK95%: 1,547 – 4,297, p = 0,002 berturut-turut). Dinilai dari kesintasan 3 tahun, pasien dengan overekspresi p53 memiliki kesintasan 3 tahun yang lebih buruk dibandingkan dengan low ekspresi (HR = 19,827 dengan IK95%: 5,974 – 65,798, p = <0,001). Begitu juga dengan overekspresi Ki67 memiliki kesintasan 3 tahun yang lebih rendah. ......Background: Naropharyngeal carcinoma (NPC) is a cancer with a fairly high prevalence in Indonesia with a fairly poor prognosis. Tumor supressor gene and cancer proliferation played an important roles in determining the progression of a cancer. This was indicated by the marker p53 as a suppressor gene that induces apoptosis and Ki67 as a marker of cell proliferation. There has been limited research on the relationship of p53 and Ki67 overexpression to the chemoradiation response and 3-year survival in locally advanced NPC. Objective: To determine the relationship between p53 and Ki67 overexpression with chemoradiation response to therapy and 3-year survival in locally advanced NPC patients. Methods: This research is an observational analytic study with a survival analysis design. This study used a retrospective cohort study design, by collecting data from medical records and then tracing the history of the disease. The research sample was tissue in the paraffin block of locally advanced NPC patients taken by consecutive sampling from the study population from period 2015–2017 at Dr. Cipto Mangunkusumo National Hospital with a total number of 82 patients. Results: From a total of 82 patients with locally advanced NPC, there were 65 male patients (79.3%) and 17 female patients (20.7%), with the most age being in the 41-50 years group as many as 31.8 %. Overexpression of p53 was found in 36 patients (43.9%), while overexpression of Ki67 was found in 35 patients (42.7%). Based on therapy response, patients with overexpression of p53 and Ki67 had a higher chance of giving a negative response compared to those with low expression (RR = 3,052 with IK95%: 1,777 – 5,242, p = 0,009; RR = 2,573 with IK95%: 1,547 – 4,297, p = 0,002 respectively). Assessed by 3- year survival, patients with p53 overexpression were statistically significantly worse than those with low-expression (HR = 19,827 with IK95%: 5,974 – 65,798, p = <0,001). Likewise, Ki67 overexpression was statistically significant and had a lower 3-year survival compared to low Ki67 expression (HR = 14,634 with IK95%: 5,074 – 42,204, p = <0,001). Conclusion: Locally advanced NPC patients with p53 overexpression and Ki67 overexpression have a tendency to give a negative chemoradiation response and have a lower 3-year survival.

Abstrak :
Latar Belakang: Kanker paru menjadi penyebab kematian utama akibat keganasan pada laki-laki sebesar 31% dan perempuan sebesar 27%. Pada pasien adenokarsinoma paru dengan mutasi pada exon 20 T790M memberikan respons yang buruk terhadap terapi EGFR-TKI generasi pertama maupun generasi kedua. Tujuan: Mengetahui profil serta angka tahan hidup 1 tahun pasien kanker paru jenis Adenokarsinoma dengan mutasi exon 20 T790M primer. Metode: Penelitian menggunakan desain kohort terhadap pasien-pasien adenokarsinoma paru stadium IV dengan mutasi exon 20 T790M primer dari bulan September 2015 sampai Desember 2017 di RSUP Persahabatan. Variabel yang diteliti adalah karakteristik klinis dan angka kesintasanberdasarkan kurva Kaplan Meier. Hasil analisis dinyatakan berbeda bermakna apabila nilai p<0,05. Hasil: Didapatkan 27 subjek penelitian dengan rerata usia 58,5 tahun dan berjenis kelamin laki-laki (70,6%). Keluhan utama berupa sesak napas (73,5%) dan nyeri dada (55,9%). Mutasi genetik tunggal pada Exon 20 T790M (64,7%), sedangkan mutasi Exon 20 T790M dengan Exon 21 L858R (11,8%) dan mutasi Exon 20 T790M dengan 21 L861Q (8,8%). Organ target metastasis adalah efusi pleura (73,5%), tulang (26,5%) dan otak (20,6%). Angka kesintasan 360 dan 990 hari sebesar 35% dan 20% dengan median kesintasan sebesar 213 hari. Kesimpulan: Mutasi exon 20 T790M pada adenokarsinoma paru memegang peranan penting terhadap kesintasan dan prediktor responsterhadap terapi yang diberikan.

---

Background: Lung cancer causes mortality in men (31%) and in women (27%). Lung adenocarcinoma patients with exon 20 T790Mepidermal growth factor receptor(EGFR) mutation showed poor response to the first generation and second generation of EGFR tyrosine kinase inhibitor (TKI) therapy. Purpose: This study aims to reveal the characteristics and one year survival rate of lung adenocarcinoma patients with primary exon 20 T790M EGFR mutations treated at Persahabatan Hospital Jakarta, Indonesia. Methods: The cohort study involved patients with primary exon 20 T790M EGFR mutation between September 2015 to December 2017 in Persahabatan Hospital Jakarta, Indonesia. The survival rate was observed from Kaplan Meier estimator curve and was statistically analyzed. Results: There were 27 subjects with mean age of 58.5 years and were predominated male (70.6%). The most common chief complaints were shortness of breath (73.5%) and chest pain (55.9%). The EGFR mutations detected were exon 20 T790M (64.7%), exon 20 T790M with exon 21 L858R (11.8%) and exon 20 T790M with exon 21 L861Q (8.8%). Metastatic target organs were pleural effusions (73.5%), bone (26.5%) and brain (20.6%). Survival rate of 360 and 990 days was 35% and 20% respectively with median survival rate was 213 days. Conclusion: Exon 20 T790M EGFR mutation in lung adenocarcinoma was revealed to be an important factor in survival and in predicting response to EGFR TKI chemotherapy.